Pixium Vision - Successful Prima activation in first US patient
Pixium Vision has announced that the first patient implanted with the Prima System in its five-patient US feasibility study in atrophic dry age-related macular degeneration has successfully undergone device activation, using the second-generation (Prima 2) transparent augmented reality glasses and pocket computer software and analytics. A second US patient has been implanted and is expected to be activated shortly. These patients were the first to have undergone treatment using Pixium’s newly developed proprietary implantation device, which is designed to facilitate the surgical technique and lower the risk of adverse effects. Our forecasts and valuation are unchanged.Pixium Vision SA is a company that specializes in sensorial neuromodulation. Co. is also collaborating with scientific groups and clinicians at research institutes and clinical centers around the world, including Stanford University (USA). Co. is developing and aims to commercialize Bionic Vision Systems (BVS) – namely active implantable medical devices to treat blindness caused by degeneration of photoreceptor cells in the retina.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.